ClinicalTrials.gg
CompletedNCT00143364Updated Jun 4, 2007

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

A Phase 3 interventional study of varenicline (CP-526,555) in Smoking Cessation, sponsored by Pfizer. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-06-04.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,005
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
6th of 110
1,005 · median 209
Started
2003
with 3 others
Phase 3
24 of 110
1 open now
Registered
4th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 6th largest by enrollment, is one of 4 that started in 2003, is one of 24 in phase 3, and was the 4th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have used bupropion (Zyban or Wellbutrin) previously.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,005 participants

Interventions

06

What researchers measure

Primary outcomes

  1. 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.

Secondary outcomes

  1. Continuous abstinence Weeks 9-52

  2. Long-term Quit Rate Week 52

  3. Continuous abstinence Weeks 9 -24

  4. 7-day Point Prevalence Abstinence Weeks 12, 24, and 52

  5. 4-week Point Prevalence Abstinence at Week 52

  6. Minnesota Nicotine Withdrawal Scale

  7. Brief Questionnaire of Smoking Urges

  8. Smoking Effects Inventory

  9. Change from baseline in bodyweight

07

Study locations

15 sites
  • Pfizer Investigational Site
    Palo Alto, California, United States
  • Pfizer Investigational Site
    San Diego, California, United States
  • Pfizer Investigational Site
    Denver, Colorado, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana, United States
  • Pfizer Investigational Site
    Portland, Maine, United States
  • Pfizer Investigational Site
    Boston, Massachusetts, United States
  • Pfizer Investigational Site
    Albert Lea, Minnesota, United States
  • Pfizer Investigational Site
    Rochester, Minnesota, United States
  • Pfizer Investigational Site
    New York, New York, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Providence, Rhode Island, United States
  • Pfizer Investigational Site
    Nashville, Tennessee, United States
  • Pfizer Investigational Site
    Madison, Wisconsin, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin, United States
08

References and documents

Publications

  • Hays JT, Croghan IT, Baker CL, Cappelleri JC, Bushmakin AG. Changes in health-related quality of life with smoking cessation treatment. Eur J Public Health. 2012 Apr;22(2):224-9. doi: 10.1093/eurpub/ckq137. Epub 2010 Sep 30. PubMed 20884658 ↗
  • Gonzales D, Jorenby DE, Brandon TH, Arteaga C, Lee TC. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. Addiction. 2010 Nov;105(11):2002-13. doi: 10.1111/j.1360-0443.2010.03058.x. Epub 2010 Sep 1. PubMed 20819082 ↗
  • Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010 Jun;12(6):574-81. doi: 10.1093/ntr/ntq047. Epub 2010 May 10. PubMed 20457644 ↗
  • Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB Jr, Williams KE. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008 Nov-Dec;32(6):664-75. doi: 10.5555/ajhb.2008.32.6.664. PubMed 18442345 ↗
  • West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008 Apr;197(3):371-7. doi: 10.1007/s00213-007-1041-3. Epub 2007 Dec 15. PubMed 18084743 ↗
  • Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63. doi: 10.1001/jama.296.1.56. Erratum In: JAMA. 2006 Sep 20;296(11):1355. PubMed 16820547 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 2, 2005
Start
Jun 2003
CompletionActual
Mar 2005
Last update
Jun 4, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00143364
Lead sponsor
Pfizer
First posted
Sep 2, 2005
Start date
Jun 2003
Completion
Mar 2005
Last update
Jun 4, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion